Chc Healthcare Group · TWSE:4164
Chc Healthcare — IPO Roadshow (October 2012)
26 slides from Chc Healthcare's IPO roadshow presentation, Oct 3, 2012
Slide 1: CHC Health Care Group IPO Press Conference
CHC Health Care Group 4164 TT IPO Press Conference Oct. 3rd 2012
Slide 2: Disclaimer
Disclaimer • The information contained in this confidential document ("Presentation") has been prepared by CHC Health Care Group (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment. • While the information contained herein has been prep
Slide 3: Executive Summary
Executive Summary • We are a leading Greater China full service solution provider for high-end Radiotherapy, Neurosurgery, Ophthalmology and Dentistry equipment. • In terms of Taiwan’s installed base of radiotherapy equipment, CHC holds a dominant 55% share (as of May 2012) via its sales of Elekta b
Slide 4: Radiotherapy is our focus
Radiotherapy is our focus • Radiotherapy sales, revenue sharing 2011 Product Mix partnerships and Dentistry, services/maintenance in Taiwan 4% accounted for 89% of 2011 revenue. Ophthalmology, 7% Radiotherapy • The superior returns on this business, and in particular on our Sales, 29% revenue sharin
Slide 5: CHC Provides a Full Spectrum of Services
CHC Provides a Full Spectrum of Services Manufacturer Clinic Planning Product Specialty Site Categories: Construction Radiotherapy CHC Health Care Group Operational Neurology Consulting Ophthalmology Revenue Distribution Services Installation Dentistry Sharing Partnerships Diagnostic Education Imagi
Slide 6: CHC's Winning Platform
CHC’s Winning Platform Over 30 Expanding years product mix experience and service in medical region devices market Increasing Medical Leading needs Solid relationship position in with Taiwan manufacturers market Experienced medical consulting team 6
Slide 7: We Know the Products, Markets and Regulations (Board)
We Know the Products, Markets and Regulations CHC BOD Members Lee, Pei-Lin MBA Ho, Chang-Jian MD Independent Director Chairman VS, National Taiwan Univ. Hospital Lee, Tien-Ying MD Chen, Gui-Duan PhD Director Independent Director Mackay Memorial Hospital ED, Taiwan CPA Association Chang, Hang MD PhD
Slide 8: We Know the Products, Markets and Regulations (Management)
We Know the Products, Markets and Regulations Management Team Yeh, Tsung-Jen Huang, Shi-Fen MBA CEO GM, Guangzhou Jiuhe GM, Philips Healthcare Sales Director, COWealth Group Lee, Tien-Ying MD Chen, Yi-Chun VP VP, Financial Accounting Dept. Mackay Memorial Hospital AVP, PricewaterhouseCoopers Lee, Mi
Slide 9: We work with world-renowned brands
We work with world-renowned brands Radiotherapy and Neurology Ophthalmology and Dentistry 9
Slide 10: We Have an Experienced Medical Consulting Team
We Have an Experienced Medical Consulting Team • CHC’s experienced consulting and service team is the critical success factor in offering medical equipment turnkey solutions to hospitals and clinics. The manufacturers in the US, Europe and Japan rely on CHC to provide this operational support and af
Slide 11: We are the Leader in Taiwan
We are the Leader in Taiwan • CHC is the market leader in Taiwan based on the solid foundation of its extensive experience in providing extra-value added turnkey solutions to health care professionals, as well as the high quality of its after sales support and maintenance services. • CHC exclusively
Slide 12: Our vision
Our vision IBA Proton Therapy Equipment Philips Nuclear Medicine and PET, MRI, CT and Interventional Product Diagnostic Imaging Equipment Medical Imaging Equipment Pipeline Swissray Radiological Imaging Equipment Product Line (Exclusive Greater China Distributor) Expansion Ophthalmology & Dentistry
Slide 13: We are Aggressively Introducing New Products
We are Aggressively Introducing New Products Diagnostic X-Ray (DR X-Ray) Computed Interventional X-Ray Tomography (CT) Proton therapy Positron Emission Tomography/ Single Magnetic Photon Emission Resonance Computed Tomography Imaging (MRI) (PET/CT & SPECT) 13
Slide 14: We are Transplanting our Model into China
We are Transplanting our Model into China • Starting in 2012, CHC established a regional distribution platform. We plan to leverage our full service solution capabilities – which have been developed over the course 30 years of experience in Taiwan – to expand our business into the China market. • We
Slide 15: CHC's China Strategy
CHC’s China Strategy • Our China team is led by veteran health care professionals with experience in the China market. • We will start building our franchise in areas of China that are demographically similar to Taiwan. • We are targeting hospitals and clinics which are managed and/or owned by Taiwa
Slide 16: CHC's Competitive Advantage in China
CHC’s Competitive Advantage in China • Complete Product Line • Successful Taiwan Experience • Full Service Solution Capability • Clinical Education • Flexible Sales Model • Cross-strait Medical Conferences 16
Slide 17: Greater China Demand for Radiotherapy Services is Strong and Growing
Greater China Demand for Radiotherapy Services is Strong and Growing • In 2011, cancer accounted for 28% and 26% of deaths, respectively, in Taiwan and China, and was the #1 cause of death in both regions. • From 2006-10, there were around 120,000 new cancer cases recorded in Taiwan annually. Radiot
Slide 18: Greater China Ophthalmology and Dentistry Market: Steady Growth
Greater China Ophthalmology and Dentistry Market: Steady Growth • Based on Taiwan Bureau of Health • There are 6,000 dental clinics in Promotion data, cataracts are the Taiwan. This number increases by an 2nd most common chronic disease avg of 80 clinics/year. Each clinic for the elderly. Yet the oc
Slide 19: Digital Radiography (DR) Market
Digital Radiography (DR) Market Global X-Ray Systems Market, Revenue Forecast China X-Ray Systems Market, Revenue Forecast US$ mn US$ mn 5000 800 Digital Analog 4500 398 390 700 Digital Analog 189 384 4000 378 178 374 600 371 169 3500 370 370 160 500 3000 151 143 2500 400 135 128 4184 4387 2000 3817
Slide 20: China Will be Driving the Growth of the Diagnostics Market
China Will be Driving the Growth of the Diagnostics Market Source: Frost & Sullivan 20
Slide 21: Diagnostic Imaging Products Account for Over 25% of the Global Medical Device Market
Diagnostic Imaging Products Account for Over 25% of the Global Medical Device Market Global Medical Device market breakdown Global Diagnostic Imaging Market breakdown Medical supply, 14.60% Bone densitometer, Others, 30.30% 2.00% Other, 0.70% CT, 9.80% X ray, 31.70% Diagnotic Imaging, 25.80% PET, 17
Slide 22: Financial Highlights
Financial Highlights NT$ mn 2500 2009-11 CAGR: Revenue: 44.2% 2000 Gross Profit: 86.6% Operating Profit: 145.9% Net Profit: 252.2% 1500 1000 500 0 2009 2010 2011 1H2012 Revenue Gross Profit Operating Profit Net Profit 22
Slide 23: 1H 2011 vs. 1H 2012
1H 2011 vs. 1H 2012 Revenue Break Down Revenue, Net Profit NT$ mn NT$ mn 400 838 900 750 800 350 339 299 700 300 244 600 250 205 500 200 172 169 400 150 300 194 100 165 83 77 200 50 100 149 0 0 1H 2011 1H 2012 Radiotherapy Sales Radiotherapy Revenue Sharing Radiotherapy Services Ophthalmology & Dent
Slide 24: Peer Comparison Charts
Peer Comparison Charts ROE Operating Margin 35% 80% 30% 28.14% 25% 23.01% 60% 57.24% 22.62% 46.12% 20% 20.15% 17.17% 17.57% 40% 37.08% 15% 26.54% 32.47% 26.63% 7.51% 20% 12.75% 28.93% 10% 8.14% 8.90% 6.64% 6.97% 8.20% 5% 5.84% 2.99% 3.96% 5.80% 5.69% 0% 6.31% 3.10% 0% 2009 2010 2011 -1.40% -20% -5%
Slide 25: Our Commitment to Shareholders
Our Commitment to Shareholders • We aim to become the leading full service health care equipment solutions provider in Greater China. • We will not sacrifice our profitability to grab market share in China. We intend to organically grow our China business on top of our healthy, successful and profit
Slide 26: Thank you
Thank you